UCB S.A.’s complement component 5 (C5) inhibitor peptide zilucoplan hit the primary endpoint and two secondary endpoints in a Phase III study in generalized myasthenia gravis (gMG), the firm announced 4 February, helping advance its two-drug strategy for the neuromuscular autoimmune disease. UCB plans regulatory filings in the US, EU and Japan later this year for both zilucoplan and for rozanolixizumab, a neonatal Fc receptor (FcRn)-targeted antibody that met the same primary endpoint in Phase III data reported in 2021.
Chris Clark, UCB’s head of asset and commercial strategy for rare diseases, told Scrip the Brussels-headquartered firm hopes its two...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)